diagnost tool
deliv strong off-set snap fecal
delay reiter buy rate pt
deliv strong result beat our/street expect rais
organ growth guid driven robust organ growth vs
new product market expans said announc second delay
snap fecal last quarter push summer
launch uncertain howev snap fecal impact small estim
next year think make grow invest
global sale forc remain best-in-class growth stock highli attract
market reiter buy rate pt look forward updat
august analyst day might learn new product updat
snap fecal delay announc reassess snap fecal test
declin offer target launch date neg surpris affirm
develop on-going hope launch futur said indic
fecal antigen test refer lab grow nice thu foregon fecal
test in-clin could theoret made send-out lab test recal
state fecal lab test snap fecal could contribut rev
year impli lost contribut snap fecal base think
sale hire announc today increas ou sale forc
direct rep earlier year increas indic
almost done hire us rais fleet
increas rep all-in look maintain leadership
rep complet acquisit abaxi yesterday
result rev organ beat
gm y/i howev expand gm
expand less invest lab om y/i beat
adj ep y/i beat
growth segment revenue beat driven beat consum
beat instrument vs estim strong growth came instrument
beat consumables/servic beat refer lab
match us follow softwar beat
lpd in-lin
sdma-on-a-slid strong indic sdma sedivu ad point
growth consum growth catalyst ib adopt sdma-
on-a-slid march great start track
survey us indic alreadi order expect order
later survey indic expect sdma test
all-in slide launch
guid rais organ growth guid
given stronger usd tighten revenue guid
rep tighten adj ep guid
vs prior
global leader anim health diagnost
instrument lab test softwar sell direct
global sale rep
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
model despit beat versu model trim
revenu estim given view
strengthen usd mitig growth rate even improv organ revenu
growth rais adj ep penni mark
midpoint guid lower revenu estim
take modestli conserv view growth
year reduc adj ep estim y/i
yet initi estim plan come
quarter lower tax rate assumpt previous
macro report patient practic data patient practic revenu growth
patient visit data
think data posit like indic data impact
advers weather view underli util vet practic strong
consist recent check
instrument growth strong deliv outstand y/i instrument
revenu growth organ exceed estim growth
place solid catalyst go intern
market go american account place premium
hematolog instrument sedivu beat snap
 american catalyst placement new competit account custom
retent rate look strong across modal
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
